A Multicentre, Double-blind, Placebo-Controlled, Randomized Trial to Assess the Efficacy and Tolerability of Two Dosing Regimens of AllerT in Adults With Birch Pollen Allergic Rhinitis

A multicentre, Double-blind, Placebo-Controlled, Randomized Trial to Assess the Efficacy and Tolerability of Two Dosing Regimens of AllerT, a Combination of Contiguous Overlapping Peptides Derived from Bet v 1, in Adults with Birch Pollen Allergic Rhinitis/Rhinoconjunctivitis

开始日期2016-09-01

申办/合作机构

Anergis SA

EUCTR2016-000076-23-SK / Not yet recruiting临床2期

A MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO ASSESS THE EFFICACY AND TOLERABILITY OF TWO DOSING REGIMENS OF ALLERT, A COMBINATION OF CONTIGUOUS OVERLAPPING PEPTIDES DERIVED FROM BET V 1, IN ADULTS WITH BIRCH POLLEN ALLERGIC RHINITIS/RHINOCONJUNCTIVITIS

开始日期2016-07-27

申办/合作机构

Anergis SA

EUCTR2016-000076-23-LT / Not yet recruiting临床2期

开始日期2016-07-11

申办/合作机构

Anergis SA

100 项与 Birch pollen allergy vaccine(Anergis) 相关的临床结果

登录后查看更多信息

100 项与 Birch pollen allergy vaccine(Anergis) 相关的转化医学

登录后查看更多信息

100 项与 Birch pollen allergy vaccine(Anergis) 相关的专利（医药）

登录后查看更多信息

项与 Birch pollen allergy vaccine(Anergis) 相关的文献（医药）

2014-07-01·The Journal of allergy and clinical immunology1区 · 医学

Safety and immunogenicity of immunotherapy with Bet v 1–derived contiguous overlapping peptides

1区 · 医学

Letter

作者: Audran, Régine ; Thierry, Anne-Christine ; Barbier, Nathalie ; Reymond, Christophe ; Spertini, François ; Charlon, Vincent ; Boudousquié, Caroline ; Pellaton, Céline ; Perrin, Yannick

This article presents the safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides.Clin. trial showed that 5 injections of AllerT administered over 2 mo elicit a strong immune response in the range of that observed after 50 injections and 3 years with other allergens and led to long-term immunol. memory were presented.Changes from baseline in Bet v 1-specific IgG4 and IgE levels were determined, and the ratios of normalized anti-Bet v 1 IgG4 and anti-Bet v 1 IgE over baseline were shown graphically.On an exploratory basis, P values for the median fold difference in IgG4 and IgE levels between AllerT- and placebo-treated patients were determined by using the nonparametric, nonpaired Mann-Whitney test.

100 项与 Birch pollen allergy vaccine(Anergis) 相关的药物交易

登录后查看更多信息

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01720251 (CTgov)	临床2期	鼻结膜炎 \| 季节性过敏性鼻炎	240	placebo (Placebo)	窪壓齋齋艱壓鹹蓋選蓋(繭鬱選鑰膚願餘鏇繭鬱) = 獵鏇簾衊膚鹽鹹鏇襯膚窪醖鬱餘製積餘鏇憲簾 (顧獵獵範淵淵構憲廠網, 廠簾積積積鹽獵顧衊簾 ~ 鹽衊廠願願醖範夢鬱繭) 更多	-	2015-04-13
				AllerT low dose (AllerT Low Dose)	窪壓齋齋艱壓鹹蓋選蓋(繭鬱選鑰膚願餘鏇繭鬱) = 餘鑰構艱鏇齋鬱簾積選窪醖鬱餘製積餘鏇憲簾 (顧獵獵範淵淵構憲廠網, 齋鹹夢夢膚齋鹹窪獵鬱 ~ 艱齋鹽淵繭築獵蓋鬱鹹)
AAAAI2014	临床2期	过敏 IgG4 \| IgE	239	50μg COPs in Aluminum hydroxide	夢製窪艱願艱願窪願蓋(廠遞繭遞築壓醖築窪範) = 4 grade 3 systemic allergic reactions (WAO grading) that occurred more than 30 min after injection (total 769 injections of active compound) 窪鏇廠獵觸淵鹽選積鑰 (觸糧壓鏇醖窪廠鏇鏇齋 )	积极	2014-02-01
				100μg COPs in Aluminum hydroxide